18F-AZA PET-CT Imaging for Cancer Diagnosis

Recruiting in Palo Alto (17 mi)

Overseen byFranklin C. Wong

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?This early phase I trial studies how well 18F-fluoroazomycin arabinoside positron emission tomography (PET)-computed tomography (CT) works in diagnosing solid tumors. Using 18F-fluoroazomycin arabinoside with PET-CT may help doctors plan better treatment for patients with solid tumors. 18F-fluoroazomycin arabinoside may help to show how much oxygen is present in a tumor during a PET-CT scan.

Eligibility Criteria

This trial is for patients with solid tumors, especially those with breast, pancreatic, or colorectal cancer. Participants must not have had recent treatment for their tumor and should have a mass at least 1 cm in size. They need to understand and sign consent forms (or have a legal representative do so if necessary) and can't start other cancer treatments during the study. Pregnant women, individuals allergic to [18F] FAZA, those over 400 pounds or with high BMI that affects imaging quality are excluded.

Inclusion Criteria

My tumor is at least 1 cm wide, confirmed by imaging tests.

I, or my legal representative if I'm unable, understand and agree to participate in the study.

I haven't had any cancer treatment in the last month.

+2 more

Exclusion Criteria

Pregnant or lactating women: pregnant women are excluded from this study because the effects of [18F] FAZA in pregnancy are not known. A urine or serum pregnancy test will be performed before accrual after informed consent is obtained.

If you weigh 400 pounds or more, or if your body size would affect the quality of the imaging tests, you cannot participate.

I am not allergic to [18F] FAZA.

+2 more

Participant Groups

The trial is testing how well an imaging compound called 18F-fluoroazomycin arabinoside works when used in PET-CT scans for diagnosing solid tumors. The goal is to see if this method can better indicate the oxygen levels in tumors which may help plan more effective treatments.

2Treatment groups

Experimental Treatment

Group I: Group B (18F-fluoroazomycin arabinoside, PET-CT scans)Experimental Treatment3 Interventions

Patients receive 18F-fluoroazomycin arabinoside IV and after 60 minutes undergo 5 or less PET-CT scans on day 1 and 5 or less PET-CT scans \>= 24 hours later up to 10 days.

Group II: Group A (18F-fluoroazomycin arabinoside, PET-CT scans)Experimental Treatment3 Interventions

Patients receive 18F-fluoroazomycin arabinoside IV and after 60 minutes undergo 5 PET-CT scans at 60, 90, 120, 150, and 180 minutes on days 1 and 2.